utcomes after carotid revascularization and medical therapy in randomized controlled trial (RCTs) have improved over time 1 ; however, their generalizability to general practice has been questioned, fueling the debate on the treatment of carotid stenosis. This is most apparent in global differences in the selection of asymptomatic patients for carotid endarterectomy (CEA). For instance, asymptomatic patients comprise a mere 2.8% of all patients undergoing revascularization in the Netherlands 2 , compared with 66% in the United States. However, it is unknown how the difference in the proportion of asymptomatic CEA patients between the United States and the Netherlands impacts the type of patients selected for revascularization or their outcomes. Thus, we compared patient characteristics and outcomes for patients undergoing CEA in the United States and in the Netherlands.
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We used the Targeted Vascular module of the National Surgical Quality Improvement Program (NSQIP) registry and the Dutch Athero-Express registry. NSQIP collected data from 89 centers, accounting for 5% of all CEAs performed in the United States annually. 4 The Athero-Express registry collected data from 2 Dutch centers, which combined accounted for >10% of all CEAs performed in the Netherlands annually.
We included all CEAs in the Targeted NSQIP from 2011 to 2015 (n=18 045) and from 2003 to 2015 in the Athero-Express (n=2318). We excluded patients with an unknown symptom status (n=368).
Thirty-day major adverse cardiovascular events (MACE; stroke/death/myocardial infarction) were our primary end point. Stroke was defined as any new ipsilateral neurological dysfunction lasting >24 hours, or when imaging indicated new cerebral infarction. Information on all other nonmodifiable variables and the data collection process for NSQIP and Athero-Express can be found online, www.facs.org/ quality-programs/acs-nsqip/program-specifics/participant-use, or in prior studies. 5 We compared American to Dutch CEA patients, stratified on symptom status, using χ 2 test, Fisher exact test, or Mann-Whitney U test, where appropriate. We performed all analyses with SPSS, and we will provide the data, analytic methods, and study materials to other researchers for purposes of reproducing the results or replicating the procedure on request. The need for institutional review board (IRB) approval was waived because of the use of deidentified data.
Of 17 699 American patients, 10 092 (57%) were asymptomatic, compared with 311 (13%) of Dutch patients (n=2318). In general, American patients, compared with Dutch patients, were more often older (Table) , female, obese, and diabetic. They less likely had contralateral carotid occlusion (CCO) and less often underwent concomitant cardiac surgery.
American asymptomatic patients experienced lower stroke rates than Dutch asymptomatic patients (1.3% versus 3.4%; P=0.007), whereas all other 30-day outcomes were similar (MACE: 3.0% versus 3.7%; P=0.5; Table) . Among symptomatic patients, all 30-day outcomes were comparable between American and Dutch patients (MACE: 4.9% versus 4.4%; P=0.5).
Moreover, on logistic regression, CCO was associated with MACE in Dutch asymptomatic patients (odds ratio, 5.8; 95% confidence interval, 1.5-23.1; P=0.01), but not in American asymptomatic patients (odds ratio, 1.3; 95% confidence interval, 0.8-2.2; P=0.3).
In this transatlantic comparison, 4× more asymptomatic patients underwent CEA in the United States than in the Netherlands. The high prevalence of CCO and lower proportions of women and octogenarians among Dutch asymptomatic patients are indicative of the differential selection of asymptomatic patients in the Netherlands, compared with the United States. Compared with Dutch asymptomatic patients, American asymptomatic patients experienced lower rates of 30-day stroke after CEA.
However, the more limited selection of Dutch asymptomatic patients for CEA has arguably resulted in a population with a higher procedural risk, illustrated by differences in the prevalence of CCO among asymptomatic patients who experienced MACE, as 6 out of every 10 Dutch asymptomatic patients with MACE had CCO (7/11, 64%), compared with 6 out of every hundred American asymptomatic patients with MACE (16/258, 6.2%). Therefore, it is likely that a proportion of low-risk asymptomatic patients, who were not selected for CEA in the Netherlands, did undergo CEA in the United States, thus potentially contributing to their better overall performance.
One explanation for our findings could be guideline disparities. On review of the European and the North American guidelines, we found that although both supported CEA for asymptomatic patients with ≥70% stenosis, the European guidelines discourage primary revascularization for patients >75 years, especially in women. 6 This correlates with the differences we identified between American and Dutch asymptomatic patients. Moreover, unwarranted global differences in guideline recommendations for the treatment of carotid stenosis in asymptomatic patients reflect the ongoing debate between surgeons, interventionists, and neurologists. 7 The main limitation of our study is the small sample of Dutch asymptomatic patients, which precluded a reliable adjusted analysis to account for the inherent bias in the outcome comparison between Dutch and American asymptomatic patients. Moreover, the Dutch cohort may not be generalizable to the entire Dutch population, as it reflects clinical practice of 2 centers. However, it does represent >10% of all CEAs performed in the Netherlands annually. Second, the Dutch registry started in 2003, compared with 2011 for NSQIP; thus, trends over time could have affected the Dutch patients more than the American patients; however, we found no trend over time in outcomes among Dutch patients. Despite these limitations, we think that our study highlights the need to critically evaluative the selection of asymptomatic patients for carotid revascularization.
